02.12.15
David Rubin is retiring from Rochester, N.Y.-based VirtualScopics Inc.’s board of directors. Taking his place as the series C shares director position is Andrew Levitch. The clinical trial imaging solutions company is also expanding its board of directors with the addition of Michael Woehler, Ph.D.
Levitch is currently a managing director of Finategy LLC, a strategic advisory firm focused on decision support at the intersection of finance and strategy, based in Clinton, N.J. He has more than 20 years of experience leading strategic, financial and operations teams in life sciences and technology companies. For more than 16 years, Levitch worked in various leadership capacities for Merck & Co. Inc., including as the senior director of Global Scientific Strategy for the company’s portfolio management activities. He received a B.S. in accounting from Rutgers College School of Business and an MBA from Lehigh University.
Woehler has more than 40 years of experience in general management, including operations, finance, marketing and business development as well as global profit and loss responsibility for multiple clinical and life science businesses. Prior leadership positions include being the president and CEO of CoreLab Partners Inc., a cardiac safety and imaging services company; the executive vice president of Parexel International Corporation, a contract life sciences and pharmaceutical outsourcing organization, where he held several senior management positions; and president, North American Holding Company of Amersham Pharmacia Biotech. Woehler received a B.A. in biology and chemistry from Northwestern University and a Ph.D. in microbiology and immunology from Marquette University.
Chairman of the Board Charles E. Phelps, Ph.D., thanked Rubin for his three-year term and welcomed the two new members to the board. “Both men bring a wealth of senior leadership experience across a wide variety of operational and organizational platforms and VirtualScopics will greatly benefit from their combined knowledge, contacts and experiences,” he said.
“I am very pleased that Andrew and Michael agreed to join our board of directors,” said Eric T. Converse, president and CEO. “Both have indicated their strong interest and desire to be ‘hands on’ directors, which will greatly assist every member of the VirtualScopics organization in the implementation and execution of our strategic growth plan. We are all very excited that they have joined our team and look forward to their contributions in the coming years.”
Levitch is currently a managing director of Finategy LLC, a strategic advisory firm focused on decision support at the intersection of finance and strategy, based in Clinton, N.J. He has more than 20 years of experience leading strategic, financial and operations teams in life sciences and technology companies. For more than 16 years, Levitch worked in various leadership capacities for Merck & Co. Inc., including as the senior director of Global Scientific Strategy for the company’s portfolio management activities. He received a B.S. in accounting from Rutgers College School of Business and an MBA from Lehigh University.
Woehler has more than 40 years of experience in general management, including operations, finance, marketing and business development as well as global profit and loss responsibility for multiple clinical and life science businesses. Prior leadership positions include being the president and CEO of CoreLab Partners Inc., a cardiac safety and imaging services company; the executive vice president of Parexel International Corporation, a contract life sciences and pharmaceutical outsourcing organization, where he held several senior management positions; and president, North American Holding Company of Amersham Pharmacia Biotech. Woehler received a B.A. in biology and chemistry from Northwestern University and a Ph.D. in microbiology and immunology from Marquette University.
Chairman of the Board Charles E. Phelps, Ph.D., thanked Rubin for his three-year term and welcomed the two new members to the board. “Both men bring a wealth of senior leadership experience across a wide variety of operational and organizational platforms and VirtualScopics will greatly benefit from their combined knowledge, contacts and experiences,” he said.
“I am very pleased that Andrew and Michael agreed to join our board of directors,” said Eric T. Converse, president and CEO. “Both have indicated their strong interest and desire to be ‘hands on’ directors, which will greatly assist every member of the VirtualScopics organization in the implementation and execution of our strategic growth plan. We are all very excited that they have joined our team and look forward to their contributions in the coming years.”